RPAM
AUPH icon

Rhenman & Partners Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Rhenman & Partners Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-125,000
Closed -$1.73M – 94
2020
Q4 		$1.73M Buy
+125,000
New +$1.82M 0.14% 79

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Rhenman & Partners Asset Management's AUPH Position: Q1 2021 in Review

Rhenman & Partners Asset Management sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2021, closing a stake of 125,000 shares — an estimated $1.73M sold.

Rhenman & Partners Asset Management first reported a position in AUPH in Q4 2020 and held it in 1 quarter. The position peaked at $1.73M in Q4 2020. 170 funds tracked by Wall St. Rank hold AUPH as of Q1 2021.

  • Rhenman & Partners Asset Management reported no remaining Aurinia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 125,000 Aurinia Pharmaceuticals shares in Q1 2021, an estimated $1.73M.
  • Rhenman & Partners Asset Management first reported a position in Aurinia Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Rhenman & Partners Asset Management's Aurinia Pharmaceuticals position peaked at $1.73M in Q4 2020.
  • 170 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2021.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2021, filed 14 May 2021.